GLP-1 Medications for Weight Loss

What are GLP-1 Medications?

• GLP-1 stands for Glucagon-Like Peptide-1.
• These medications mimic a natural hormone your body produces, mainly in the gut, after you eat.
• Originally developed for Type 2 Diabetes, some are now TGA-approved for weight management.
• They work by making your brain feel full, slowing digestion, and helping regulate blood sugar.
• Most are injectable, typically once weekly or daily, using a pre-filled pen device.
• They are a key part of science-backed weight loss programs, not a standalone solution.

How Do GLP-1 Medications Work?

GLP-1 medications work by mimicking the natural GLP-1 hormone, producing three key effects:

• 1. Reduce Appetite & Cravings: They act on areas of your brain (hypothalamus) to decrease hunger signals and increase feelings of fullness. You may find you don't think about food as much.
• 2. Slow Digestion (Gastric Emptying): Food stays in your stomach longer, extending the feeling of being full after meals. This means you feel satisfied for longer.
• 3. Regulate Blood Sugar: They stimulate insulin release from the pancreas and suppress glucagon, stabilizing blood sugar levels. This can reduce energy crashes and cravings.

Dual GIP/GLP-1 agonists (like Tirzepatide) work on two similar hormone pathways (GLP-1 and GIP) for even stronger effects on weight loss.

GLP-1 & Related Medications in Australia

TGA-Approved Options for Weight Management (as of July 2026, subject to change)

Who Is Eligible for GLP-1s in Australia?

Eligibility is determined by your GP through a comprehensive clinical assessment, following established medical guidelines.

• General Criteria (NHMRC, RACGP):
  • BMI of 30 kg/m² or above, OR
  • BMI of 27 kg/m² or above with at least one weight-related comorbidity (e.g., Type 2 Diabetes, high blood pressure, sleep apnoea, dyslipidaemia, PCOS, insulin resistance).
• Lower Thresholds for Specific Backgrounds: For patients of Asian, South Asian, Aboriginal, and Torres Strait Islander backgrounds, weight-related health risks can appear at lower BMI ranges, leading to adjusted thresholds (e.g., PBS eligibility at BMI 32.5 for cardiovascular history).
• Prescription Only: Must be prescribed by a registered medical practitioner following a full clinical assessment. Not available over-the-counter.

Efficacy: What Weight Loss to Expect

Significant Results from Clinical Trials:

• Large-scale trials (e.g., STEP studies) demonstrate average weight reductions of **15% to 22% of body weight** over 68 weeks when combined with lifestyle changes.
• For someone weighing 120 kg, this could mean losing 18 to 26 kg.
• Weight loss is often accompanied by measurable improvements in:
  • Blood pressure
  • Cholesterol
  • Blood sugar markers (HbA1c)
  • Cardiovascular risk

Comparative Efficacy (Average body weight reduction at highest approved dose):

• Mounjaro (Tirzepatide): ~21%
• Wegovy (Semaglutide): ~15-17%
• Ozempic (Semaglutide, off-label): ~15%
• Saxenda (Liraglutide, discontinued): ~8%
• Contrave: ~5-8%
• Orlistat: ~3-5%

Weight Regain is Common if Treatment Stops

• Obesity is a chronic condition: GLP-1 medications are a management tool, not a "cure."
• Long-term Use is Key: For most patients, maintaining weight reduction requires continuous use of these medications.
• **Combined Approach:** This must be coupled with ongoing lifestyle modifications (diet, exercise) and multidisciplinary support.
• Trial Evidence: One study showed that 12 months after stopping Semaglutide, the proportion of participants who maintained ≥5% weight loss dropped significantly from 86.4% to 48.2%.
• Composition of Regain: Concern exists that weight regained might be disproportionately fat rather than muscle, which carries additional health risks. Support for building and maintaining muscle throughout treatment and after is important.

Approximate Annual Costs (Australia)

Private/out-of-pocket monthly costs Without PBS subsidy, GLP-1 medications are significant.

• Current Out-of-Pocket Costs: Without PBS subsidy, between $300 - $450 AUD per month (approx. $3,600 - $5,400 per year), depending on the specific medication, dosage, and pharmacy.
• Examples (Monthly Private Cost):
  • Ozempic (for Diabetes only): ~$134
  • Wegovy: $350 - $460
  • Mounjaro: From $395
  • Contrave: $150 - $200
  • Orlistat: $50 - $80 (OTC available)
• Some subscription-based telehealth services may add platform fees, increasing total costs.
• Affordability and access are substantial barriers for many individuals.

PBS Subsidy: Transforming Access (2026)

• Ozempic (Semaglutide): Currently PBS-subsidised for **Type 2 Diabetes only**. Not for weight management.
• Wegovy (Semaglutide):
  • PBAC recommended PBS listing in January 2026 for weight management.
  • Initial PBS Criteria: Adults with BMI ≥35 (or ≥32.5 for Asian, Aboriginal, Torres Strait Islander populations) AND established cardiovascular disease (e.g., prior heart attack, stroke).
  • Price negotiations ongoing with government.
  • **If listed:** Costs would drop to ~$31.60 per script (general patients) or ~$7.70 (concession card holders).
• Mounjaro (Tirzepatide): Currently **not PBS listed** for weight management or diabetes.
• Orlistat/Contrave: Not PBS listed for weight management.

Common Side Effects (First 4-6 Weeks)

Most patients experience some mild-to-moderate side effects, especially when starting the medication or increasing the dose.

• Nausea: Most frequently reported. Tends to be mild-to-moderate, common in the first 2-4 weeks, and usually settles as your body adjusts to each new dose.
  • Management: Smaller, frequent meals; avoid high-fat foods; stay hydrated; discuss timing with GP.
• Constipation: Common, due to slowed gastric emptying.
  • Management: Increase fibre and water intake.
• Diarrhea & Vomiting: Can occur, usually resolves within a few weeks.
• Fatigue/Low Energy: May occur early, often resolves as your body adapts to new caloric intake.
• Reduced Appetite: The intended therapeutic effect, but can be more pronounced initially.

Less Common Side Effects

• Injection Site Reactions: Redness, itching, or mild swelling at the injection site (with injectable forms).
  • Management: Rotate injection sites; proper technique (your GP or pharmacist will demonstrate).
• Acid Reflux / Heartburn: Can occur due to changes in gastric motility. Your doctor may adjust dose or add reflux medication.
• Dizziness
• Mild Tachycardia (Increased Heart Rate)
• Infections
• Headaches
• Indigestion (Upset Stomach)

Rare but Serious Side Effects

These require immediate medical attention and close monitoring by your GP:

• Pancreatitis: Inflammation of the pancreas. Symptoms include severe abdominal pain (often radiating to the back), nausea, and vomiting. **Seek urgent medical care if these occur.**
• Gallstones: A slightly higher risk in patients experiencing rapid weight loss, regardless of the method. Monitoring may be recommended if you have a history of gallbladder issues.
• Thyroid Concerns: Specific GLP-1 formulations may require review of thyroid history during assessment.
• Acute Kidney Injury: While rare, it's a potential risk.
• Worsening Diabetic Retinopathy: Has been reported, particularly with rapid blood sugar changes in some individuals with pre-existing diabetic eye disease.
• Allergic Reactions: Ranging from injection site reactions to severe anaphylaxis (rare but serious).

Patient Perspective: "Is it Worth the Side Effects?"

• High Motivation: Many patients are highly motivated and willing to accept common adverse events (e.g., gastrointestinal issues like nausea) for successful weight loss.
• Improved Quality of Life: Patients report significant improvements in physical functioning, overall well-being, and active daily living as a result of weight loss. This positive impact often outweighs the perceived discomfort of side effects.
• "Worth Anything to Lose Weight": Some patients explicitly state they will "put up with anything" to achieve weight loss.
• Nausea as a Signal: Some individuals even interpret initial nausea as a sign that the treatment is actively working.
• Economic Burden: Patients have shown a willingness to pay substantial out-of-pocket costs, underscoring the perceived value of these medications.

Patient Challenges & Mental Health Impacts

• Usability Challenges: Diverse opinions on injections. Some dislike self-injection, while others find monthly/weekly injections simpler than daily pills that have timing restrictions (e.g., "take on empty stomach").
• Impact on Relationship with Food: These medications can interfere with the pleasure of eating.
  • This can complicate assessment for other serious illnesses (infection, cancer, depression, or eating disorders).
  • May exacerbate mental health conditions (depression, suicidal ideation) – an area of active research.
• Potential Misuse: Risk of use by individuals without obesity, particularly those with eating disorders. Appetite suppression can lead to self-starving or poor nutritional intake. Your GP can help manage these requests appropriately.
• Impact of Non-response: There is limited research on the mental health impact for those who do not respond to the drugs. Clinical trials show that 10-15% of participants may not achieve significant weight loss.

Beyond the Prescription: Why Your GP Matters

• Holistic View: Your GP reviews your full health history, current medications, previous weight loss attempts, and mental health. This context is vital for safe and effective care.
• Structured Pathway: Your GP manages the entire process: initial assessment, prescription, dose titration, ongoing monitoring, and long-term care.
• Managing Side Effects: Your GP guides you through potential side effects, offering management strategies (dose adjustment, dietary advice, supportive medications).
• Catching Complications: GPs monitor blood work for subtle changes (e.g., liver, thyroid function) and watch for rare but serious side effects. They can intervene early if issues arise.
• Continuity of Care: An ongoing relationship with the same GP leads to better treatment adherence, more effective side effect management, and improved long-term weight maintenance.

Your Journey: Recommended GP Visit Schedule

Are GLP-1 Medications Right for Me? (Key Considerations)

Important Risks & Discussion Points:

• Allergic Reactions: Can occur, from injection site reactions to severe anaphylaxis (rare).
• Pregnancy & Conception: Not safe during pregnancy. Effective contraception is advised. Stop medication well before conception (1-2 months, depending on drug).
• Hypoglycemia (Low Blood Sugar): Low risk when used alone. Significantly increases if combined with other blood-sugar-lowering medications (e.g., insulin, sulfonylureas). Symptoms: shaking, sweating, dizziness, confusion.
• Disordered Eating & Body Image: Careful screening is needed to ensure medications do not exacerbate existing eating disorders or drive unhealthy weight goals.
• Expense & Long-term Commitment: Consider the high out-of-pocket costs without PBS subsidy and the need for long-term use.

Your Questions Answered (FAQ)

Eligibility & Prescribing:

Q: Is GLP-1 medication covered by the PBS in Australia?
A: PBS coverage is expanding, but eligibility depends on specific medication and your clinical situation. Ozempic is for Type 2 Diabetes only. Wegovy listing is pending for specific weight management criteria. Your GP can advise on current status.

Q: Can I get GLP-1 medication prescribed through telehealth?
A: Yes, an online GP can assess eligibility, discuss options, and prescribe if clinically appropriate, with regular follow-up for safe and effective treatment.

Q: Who is eligible for GLP-1 weight loss medication in Australia?
A: Eligibility is generally based on BMI and the presence of weight-related health conditions, determined by your GP after a full assessment.

Side Effects:

Q: What side effects should I expect?
A: Most common are nausea, reduced appetite, and digestive discomfort (especially early on). These typically improve over time as the dose is gradually increased. Your GP monitors your response and adjusts treatment as needed.

Additional Resources & Information

• Your General Practitioner (GP): Your most important first point of contact for personalized medical advice, assessment, and ongoing management.
• Australian Prescriber: A reputable source for independent, evidence-based information on medications (www.australianprescriber.tg.org.au).
• RACGP (Royal Australian College of General Practitioners) / NHMRC (National Health and Medical Research Council): Official bodies providing clinical guidelines for Australian healthcare professionals.
• Department of Health, Disability and Ageing (Australian Government): For official health information and updates on PBS listings (www.health.gov.au).
• Weight Loss Information Websites: (e.g., www.weightloss.com.au, www.abbyhealth.app) can provide general overviews, but **always consult your GP** for specific medical advice.
• Patient Support Groups: May offer peer support and shared experiences (discuss with your GP if appropriate).

Key Takeaways & Important Disclaimer

Key Takeaways:

• Not a Standalone Solution: GLP-1s are effective tools WHEN integrated into a holistic, multidisciplinary approach involving diet, exercise, behavioural changes, and consistent medical supervision.
• Long-Term Commitment: Lifelong treatment is typically required for sustained weight loss, and weight regain is common if the medication is stopped without continued support.
• Personalized Care: Your response to GLP-1s, including efficacy and side effects, is individual. Close collaboration with your GP is essential.

Important Disclaimer: